New Phase 3 trial: A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer — Jiangsu Simcere Pharmaceutical Co., Ltd.

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-19 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES0

STORY SIZESTANDALONE

FIRST SEEN2026-10-19 12:00 UTC

LAST UPDATE2026-10-19 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Status: Active Not Recruiting; Conditions: Myelosuppression; Interventions: Trilaciclib, Trilaciclib Placebo, Etoposide Injection; Enrollment: 106 (actual); First posted: 2026-10-19; NCT: NCT07881705

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-19 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
AMD filed 4 on 2026-10-192026-10-19 00:00 UTC

←INFERENCEfilings generate company commentary
MA filed 4 on 2026-10-192026-10-19 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.